Turning Ideas Into Drugs
Biotech firms rely on contract manufacturers for help and guidance on the road to market for new molecules
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
March 4, 2013 Cover
Volume 91, Issue 9
Biotech firms rely on contract manufacturers for help and guidance on the road to market for new molecules
Cover image:
Credit:
Biotech firms rely on contract manufacturers for help and guidance on the road to market for new molecules
A potpourri of analytical techniques reveals purported Aztec sculptures are not bona fide
Chemists debate the best way to use reaction data to compare catalyst efficiencies
Money and accomplished scientists boost efforts to build world-class pharmaceutical institutes
Science advisers to suggest improvements for work on computational toxicology, cost estimates of regulations
Fourth-quarter chemical earnings increase as the industry learns to boost profit margins even as sales stagnate
Catalytic metal particles embedded in monolayers of chiral molecules yield solid catalysts that facilitate enantioselective reactions